Advertisement

After nearly a decade of quiet research, DecImmune Therapeutics Inc. of Cambridge has announced a new $1 million equity financing round, from new investor Astellas Venture Management and previous investors Amgen Ventures and HealthCare Ventures.

At the same time, the company, which started life in 2001 as Natural Antibodies Inc., reported it was awarded $2.2 million in Phase II SBIR funding from the National Institutes of Health. The combined $3.2 million in funding will go to speeding up development of the company’s therapy to treat ischemia reperfusion injury, the damage that occurs to blood vessels and tissue when blood flow is blocked, resulting in swelling.

SOURCE

Advertisement
Advertisement